GeoVax Labs Files 8-K on Financials
Ticker: GOVX · Form: 8-K · Filed: Aug 7, 2024 · CIK: 832489
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: GOVX
TL;DR
GeoVax Labs dropped an 8-K on August 6th detailing their financial condition. Check it for the latest numbers.
AI Summary
On August 6, 2024, GeoVax Labs, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, providing an update on the company's fiscal performance. GeoVax Labs, Inc. is incorporated in Delaware and its fiscal year ends on December 31st.
Why It Matters
This filing provides investors with an update on GeoVax Labs' financial health and operational results, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant financial and operational updates, which may introduce volatility depending on the disclosed information.
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- August 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39563 (identifier) — SEC File Number
- 87-0455038 (identifier) — IRS Number
FAQ
What is the primary purpose of this 8-K filing for GeoVax Labs, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported was on August 6, 2024.
In which U.S. state is GeoVax Labs, Inc. incorporated?
GeoVax Labs, Inc. is incorporated in Delaware.
What is the SEC file number for GeoVax Labs, Inc.?
The SEC file number for GeoVax Labs, Inc. is 001-39563.
When does GeoVax Labs, Inc.'s fiscal year end?
GeoVax Labs, Inc.'s fiscal year ends on December 31st.
Filing Stats: 621 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-08-07 16:05:39
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M
Filing Documents
- govx20240806_8k.htm (8-K) — 28KB
- ex_709669.htm (EX-99.1) — 93KB
- geovax.jpg (GRAPHIC) — 5KB
- 0001437749-24-025175.txt ( ) — 285KB
- govx-20240806.xsd (EX-101.SCH) — 4KB
- govx-20240806_def.xml (EX-101.DEF) — 13KB
- govx-20240806_lab.xml (EX-101.LAB) — 17KB
- govx-20240806_pre.xml (EX-101.PRE) — 13KB
- govx20240806_8k_htm.xml (XML) — 5KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and other reports filed by the Company from time to time with the Securities and Exchange Commission (collectively the "Filings") contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company's management as well as estimates and assumptions made by the Company's management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to the Company or the Company's management identify forward looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Company's industry, operations and results of operations and any businesses that may be acquired by the Company. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Except as required by law, the Company does not undertake to update its forward-looking statements.
02
Item 2.02 Results of Operations and Financial Condition. On August 6, 2024, GeoVax Labs, Inc. (the "Company") issued a press release reporting its results of operations for the quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 7, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer 3